Systemic lupus erythematosus (SLE) often presents with neuropsychiatric (NP) involvement, including cognitive impairment and depression. Past magnetic resonance imaging (MRI) research in SLE patients ...

EULAR/ACR SLE classification criteria were not linked to mortality or hospitalization, a developed ominosity model adequately predicted mortality.

Objective Evaluating the potential role of neuromuscular ultrasonography (NMUS) in assessing optic nerve affection in ...

Results showed that systemic lupus carries the greatest risk for heart health, more than doubling a person’s risk of heart ...

Medically reviewed by Aviv Joshua, MS Vitamin D levels can be measured with a blood test. This test can indicate whether you have adequate levels, are at risk of a vitamin D deficiency, or have levels ...

IT is becoming generally accepted that many cutaneous abnormalities are symptomatic of general diseases and, therefore, that a disease may have in common various manifestations detectable in ...

Ongoing commercial launch of AUCATZYL® on track, with 24 treatment centers fully authorized as of January 10th- National Comprehensive Cancer ...

Bullous systemic ... systemic lupus erythematosus (SLE). It causes blisters on the skin and may affect the internal organs. SLE is a complex condition that can have a range of symptoms affecting ...

On average, lupus symptoms in older people begin at around age 59 ... Stefanidou S, Gerodimos C, Benos A, et al. Clinical expression and course in patients with late onset systemic lupus erythematosus ...

In a new study published in Lupus Science & Medicine, researchers reviewed randomized clinical trials (RCTs) to assess therapies for initial management of lupus nephritis (LN), focusing on their ...

In the Phase 2b CARE study, the investigational drug, cenerimod, demonstrated safe and effective results for treatment of adults with moderate-to-severe systemic lupus erythematosus (SLE ... Lupus ...

Antolin J, Amerigo MJ, Cantabrana A, Roces A, Jimenez P: Systemic lupus erythematosus: clinical manifestations and immunological parameters in 194 patients. Subgroup classification of SLE.